FMTVDM Sovereign Standard™ Series — Part II
- Richard M Fleming, PhD, MD, JD
- 18 hours ago
- 3 min read
Cancer: The Disease of Guessing — and the End of Guesswork
For decades, cancer diagnosis has relied on qualitative imaging, biopsy interpretation, and statistical risk models.
Patients are told to wait, watch, or undergo treatment based on what a radiologist “sees” or what a pathologist “thinks.”
This approach has led to missed diagnoses, overtreatment, and a global epidemic of uncertainty.
The FMTVDM measurable-era changes everything.
FMTVDM is the only patented method that quantifies the InflammoThrombotic Immunologic Response Disease (ITIRD) known as cancer. It measures where someone is on the ITIRD continuum — and whether treatment is working or failing.
1. From BEST to FMTVDM: The Evolution of Quantification
Early versions of FMTVDM used for breast cancer imaging were known as Breast
Enhanced Scintigraphy Test (BEST). These studies demonstrated that:
Mammography misses disease in dense breasts
Qualitative imaging cannot distinguish inflammation from cancer
Quantitative measurement of regional blood flow and metabolism reveals true disease
As research progressed, it became clear that FMTVDM could measure ITIRD across multiple organ systems — not just the breast. With the advent of whole-body nuclear imaging cameras, FMTVDM now quantifies ITIRD across the entire body in a single imaging session.
2. The Gompertz Function, Laird Model, and FMTVDM® Alignment
The Alignment paper confirms what the FMTVDM measurable-era demands:
FMTVDM measurements follow the Gompertz and Laird growth curves
Cancer is not a binary state — it is a continuum of tissue change
FMTVDM quantifies transitional tissue before cancer fully develops
Treatment response can be tracked in real time
This is not theory.
It is published, reproducible, and independently validated.
3. The Reno Cardiologist Study: Independent Validation of FMTVDM
In Reno, Nevada, a private practice cardiologist — with no prior experience in molecular breast imaging — successfully performed FMTVDM for both heart disease and breast cancer.
The Reno Cardiologist paper shows:
FMTVDM protocols and A.I.2 programming enable rapid training
Nuclear laboratories can be credentialed to perform FMTVDM
The same camera used for MPI can be used for cancer imaging
FMTVDM is reproducible across centers, regardless of prior expertise
This was the first independent validation that FMTVDM is deployable at scale.
4. Hormone Therapy, Smoking, and the Measurable Truth
The HRT and Delta Tissue studies reveal what qualitative medicine has missed:
Women taking hormone therapy have higher rates of cellular atypia and breast cancer
Smoking is associated with increased breast tissue abnormalities
FMTVDM quantifies metabolic and vascular changes — not just anatomical findings
These changes are measurable before cancer fully develops
These were the first published research studies to confirm that smoking and hormone replacement therapy was associated with an increased risk of cancer
This is the first published research showing that lifestyle factors and cancer can be measured — not guessed — using FMTVDM.
5. Soy Protein: What Helps One Person May Harm Another
The Soy paper demonstrates a critical truth:
Soy protein reduced fibrocystic disease in some women
In others, it increased metabolic activity consistent with increased cancer risk
Only FMTVDM can accurately determine by measurement whether a dietary intervention, or medical treatment is helping or harming
The food pyramid cannot be trusted — only measurement reveals truth
This is why guessing — even with “healthy” interventions — can cause harm.
FMTVDM ends the guessing.
6. The ITIRD Continuum: Measuring Cancer Before It’s Cancer
FMTVDM quantifies:
Metabolically inert tissue
Expected (normal) tissue
Inflammation
Late-stage inflammation
DCIS and developing cancers
Further cancer transition
Cancer
This is not a spectrum of opinion.
It is a spectrum of measured reality.
7. The Sovereign Standard for Cancer Diagnosis
FMTVDM is the only method that:
Quantifies regional blood flow and metabolism
Tracks treatment response over time
Works with existing nuclear cameras
Can be deployed in any credentialed center
Removes human error and qualitative bias
This is the Sovereign Standard™ for cancer diagnosis.
It is reproducible.
It is deployable.
It is measurable.
8. What Comes Next — Part III: Infection
This is Part II of the FMTVDM Sovereign Standard™ Series:
Part I — Heart Disease: How FMTVDM ends the era of blood test guessing and reveals true CAD.
Part II — Cancer: How FMTVDM quantifies ITIRD, tracks treatment, and confirms Gompertz-Laird growth.
Part III — Infection: How FMTVDM detects and measures inflammatory and infectious processes invisible to conventional imaging.
Comments